Eli Lilly and Company (NYSE:LLY) Shares Purchased by Farmers & Merchants Investments Inc.

Farmers & Merchants Investments Inc. lifted its position in Eli Lilly and Company (NYSE:LLY) by 0.1% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 49,930 shares of the company’s stock after acquiring an additional 31 shares during the period. Eli Lilly and Company accounts for approximately 1.3% of Farmers & Merchants Investments Inc.’s investment portfolio, making the stock its 12th biggest holding. Farmers & Merchants Investments Inc.’s holdings in Eli Lilly and Company were worth $38,844,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Lipe & Dalton acquired a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $26,000. Tidemark LLC acquired a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $29,000. Core Wealth Advisors Inc. grew its position in shares of Eli Lilly and Company by 188.2% during the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after acquiring an additional 32 shares during the period. Frank Rimerman Advisors LLC acquired a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $37,000. Finally, St. Johns Investment Management Company LLC grew its position in shares of Eli Lilly and Company by 123.3% during the 4th quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company’s stock valued at $39,000 after acquiring an additional 37 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 58,749 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $915.26, for a total value of $53,770,609.74. Following the completion of the transaction, the insider now owns 97,308,620 shares in the company, valued at $89,062,687,541.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CAO Donald A. Zakrowski sold 750 shares of Eli Lilly and Company stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the sale, the chief accounting officer now directly owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 58,749 shares of Eli Lilly and Company stock in a transaction on Monday, July 1st. The stock was sold at an average price of $915.26, for a total transaction of $53,770,609.74. Following the sale, the insider now directly owns 97,308,620 shares of the company’s stock, valued at $89,062,687,541.20. The disclosure for this sale can be found here. Insiders sold a total of 849,894 shares of company stock worth $727,475,118 over the last 90 days. Corporate insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on LLY shares. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Jefferies Financial Group raised their price target on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research note on Monday, June 24th. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Argus raised their price target on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research note on Tuesday, May 14th. Finally, Truist Financial reissued a “buy” rating and issued a $1,000.00 target price (up from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $812.72.

Eli Lilly and Company Stock Down 0.8 %

Eli Lilly and Company stock opened at $906.71 on Wednesday. The firm has a 50 day moving average price of $818.06 and a 200 day moving average price of $743.26. The company has a market capitalization of $861.75 billion, a PE ratio of 133.54, a price-to-earnings-growth ratio of 1.97 and a beta of 0.41. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. Eli Lilly and Company has a fifty-two week low of $434.34 and a fifty-two week high of $916.83.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.53 by $0.05. The business had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The company’s quarterly revenue was up 26.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.62 earnings per share. Research analysts expect that Eli Lilly and Company will post 13.76 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be paid a $1.30 dividend. The ex-dividend date is Thursday, August 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.57%. Eli Lilly and Company’s dividend payout ratio (DPR) is 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.